Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl salicylate is a small molecule topical analgesic and counter-irritant primarily used for the symptomatic relief of minor musculoskeletal pain such as that associated with arthritis, backache, sprains, strains, bruises, and neuralgia. It is commonly found in over-the-counter creams and patches. Methyl salicylate acts by causing irritation of the skin (rubefacient effect), which leads to vasodilation and a sensation of warmth that distracts from deeper musculoskeletal pain. Mechanistically it penetrates the skin to reversibly inhibit cyclooxygenase enzymes (COX), thereby reducing local production of inflammatory mediators like prostaglandins and thromboxane A2. It is structurally related to aspirin (acetylsalicylic acid) but used topically rather than systemically[1][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl salicylate.